MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma

Kendall, J. orcid.org/0000-0003-2884-4849, Hall, A., Roberts, S. et al. (5 more authors) (2022) MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma. BMJ Open, 12 (10). e062504. ISSN 2044-6055

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Dates:
  • Published: 26 October 2022
  • Published (online): 26 October 2022
  • Accepted: 11 August 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 27 Feb 2025 10:27
Last Modified: 27 Feb 2025 10:29
Published Version: https://bmjopen.bmj.com/content/12/10/e062504
Status: Published
Publisher: BMJ
Identification Number: 10.1136/bmjopen-2022-062504
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics